ALG8-Congenital Disorder of Glycosylation (ALG8-CDG) is a rare, inherited disease. It happens when a child gets two faulty copies of the ALG8 gene—one from each parent. The ALG8 gene makes an enzyme in the endoplasmic reticulum that helps build a sugar tree (a glycan) before it is attached to many proteins. If ALG8 does not work, these sugar trees are not built correctly. As a result, many proteins around the body are not finished properly. This problem affects many organs at the same time, especially the intestine, liver, brain, eyes, blood, and muscles. Doctors call this family of diseases congenital disorders of glycosylation (CDG). ALG8-CDG used to be called CDG type Ih. There is no specific cure yet; care focuses on managing symptoms and preventing complications. CDG Hub+3CDG Hub+3Orpha.net+3
Inside our cells, new proteins need a small sugar tree to help them fold, travel, and work. ALG8 is a glucosyltransferase that adds a glucose (a sugar) to a growing sugar tree on a lipid called dolichol. This building job happens on the ER membrane. If ALG8 is missing or weak, the sugar tree is unfinished. Then many proteins are poorly glycosylated, misfold, and may be removed, which stresses cells and organs. UniProt+2GeneCards+2
ALG8-CDG is a rare, inherited metabolic disease. It happens when a child receives two non-working copies of a gene called ALG8 (one from each parent). The ALG8 gene gives the body instructions to make an enzyme that adds a small sugar (a glucose) to a growing sugar chain inside the cell’s “protein factory,” the endoplasmic reticulum. This sugar-adding step is part of N-glycosylation—a process cells use to decorate many proteins with sugars so those proteins can fold, travel, and work properly.
When ALG8 does not work, the “sugar chain” is left unfinished at an early step. Many proteins are then under-glycosylated (missing sugars), so they cannot do their normal jobs. Because glycoproteins are needed everywhere, the disease can affect many body systems: the gut (feeding problems and protein-losing enteropathy), liver, blood clotting, brain and nerves, heart, kidneys, eyes, bones, skin, and hormones. Severity ranges from mild disability to very serious, even life-threatening disease in infancy. hssiem.org+1
Other names
ALG8-CDG
Congenital disorder of glycosylation type Ih (CDG-Ih) – the older subtype name within the “type I” (assembly/transfer) CDGs
ALG8 deficiency
Dolichyl-P-glucose:Glc1Man9GlcNAc2-PP-dolichyl α-1,3-glucosyltransferase deficiency (technical)
Sometimes described historically as glucosyltransferase II deficiency (ALG6 is “I”, ALG8 is “II”). CDG Hub+2PubMed+2
Types
There are no official subtypes of ALG8-CDG, but clinicians recognize patterns of how it can present. Grouping by pattern helps families and teams know what to monitor:
Severe neonatal form – Very early onset with feeding problems, low blood proteins, swelling (edema), liver involvement, coagulopathy, and often serious complications. Some infants have life-threatening disease very early. hssiem.org
Classic infantile multisystem form – Hypotonia, developmental delay, seizures (sometimes), protein-losing enteropathy (PLE), liver and clotting problems, plus dysmorphic facial features; survival into childhood with ongoing needs. PubMed+1
Childhood survivors with neuro-gastro-hepatic features – Developmental disability (stable or slowly changing), ongoing PLE or constipation/GERD, variable endocrine or cardiac issues. hssiem.org
Attenuated/adolescent–adult presentations – Milder disability; may include neuropsychiatric features (e.g., autism spectrum traits), ocular findings, skeletal problems, cardiac rhythm changes, or lipid abnormalities; careful surveillance is advised. hssiem.org
Causes
Note: the root cause is biallelic pathogenic variants in ALG8. Items below explain the main cause and the many downstream mechanisms and modifiers that “cause” specific features or make them worse.
Biallelic pathogenic ALG8 variants (autosomal recessive inheritance). Both copies must be altered for disease. hssiem.org
Missense variants that reduce enzyme activity. hssiem.org
Nonsense or frameshift variants that truncate the enzyme. hssiem.org
Splice-site variants that disrupt correct mRNA processing. hssiem.org
Partial gene deletions affecting ALG8 exons. hssiem.org
Failure to add the second glucose to the lipid-linked oligosaccharide (the exact ALG8 step). hssiem.org
Accumulation of incomplete sugar chains (Glc1Man9GlcNAc2-PP-dolichyl) and shortage of complete chains for transfer to proteins. hssiem.org
Global hypoglycosylation of glycoproteins, causing poor protein folding/stability across organs. NCBI
Coagulation factor under-glycosylation, leading to low antithrombin, protein C, and factor XI → bleeding/clotting issues. NCBI
Enterocyte and glomerular basement membrane glycan defects, which can cause PLE and proteinuria. hssiem.org
Liver glycoprotein defects → elevated transaminases, hepatomegaly. Orpha.net
Endocrine glycoprotein changes (e.g., TSH, IGF system) → hypothyroidism, growth issues, hypoglycemia. hssiem.org
Neural glycoprotein dysfunction → hypotonia, seizures, developmental delay. Frontiers in Glycosylation
Cardiac glycoprotein/ion channel effects → structural anomalies or rhythm problems (e.g., prolonged QT). hssiem.org
Renal tubulopathy or cystic changes related to glycan defects. hssiem.org
Skeletal matrix glycosylation defects → osteopenia and fracture risk. hssiem.org
Ocular glycoprotein abnormalities → cataract/retinal findings in some patients. hssiem.org
Intercurrent infection as a trigger of decompensation (worsening seizures/hypotonia/PLE). hssiem.org
Nutritional stress or illness that increases protein loss and unmasks PLE or coagulopathy. (Inference consistent with PLE physiology in ALG8-CDG.) hssiem.org
Genetic background (modifier genes) and environment, which may explain the broad range from mild to severe disease. hssiem.org
Common symptoms and signs
Low muscle tone (hypotonia). Infants feel “floppy,” delay in head control and sitting. hssiem.org+1
Developmental delay (speech, motor, cognition), sometimes stable into later childhood. hssiem.org
Seizures (varied types: infantile spasms, myoclonic, focal, febrile-triggered). hssiem.org
Feeding problems (poor suck, reflux, vomiting), often from birth. Orpha.net
Chronic diarrhea or constipation; protein-losing enteropathy may cause low albumin. hssiem.org+1
Failure to thrive / poor growth despite calories, driven by malabsorption and PLE. hssiem.org
Edema and puffiness (from low blood protein), sometimes with ascites. Orpha.net
Liver involvement (hepatomegaly; elevated enzymes). Orpha.net
Bleeding or easy bruising (coagulation factor deficiencies). NCBI
Recurrent infections or inflammatory flares that worsen other symptoms. hssiem.org
Cardiac issues (heart murmurs, structural changes, rhythm problems like prolonged QT). hssiem.org
Kidney problems (proteinuria; rarely microcysts; electrolyte issues). hssiem.org
Eye findings (abnormal movements; rarely cataract; occasional retinal changes). hssiem.org
Skeletal problems (osteopenia, fractures) and sometimes musculoskeletal differences. hssiem.org
Endocrine concerns (hypothyroidism; sometimes hypoglycemia/hyperinsulinism). hssiem.org
Diagnostic tests
A) Physical examination
General growth and nutrition assessment. Measures weight/length/head size and looks for signs of malnutrition or edema; helps flag PLE or chronic illness. Orpha.net
Neurologic exam for hypotonia and reflexes. Low tone, weak reflexes, or ataxia suggest neurologic involvement. Frontiers in Glycosylation
Abdominal exam. Checks for hepatomegaly, tenderness, or ascites from liver disease or low albumin. Orpha.net
Skin and facial features review. Wrinkled skin/fat pads or subtle dysmorphic features can support a CDG suspicion. hssiem.org
B) Manual/bedside tests
Developmental screening (e.g., Bayley, Denver). Quantifies delays to guide therapy and baseline tracking. (Standard pediatric practice for developmental disorders.)
Bedside eye exam (pupil reflex, cover–uncover, tracking). Screens for ocular movement issues or visual impairment reported in ALG8-CDG. hssiem.org
Ataxia maneuvers (tandem gait, finger-to-nose, heel-to-shin). Simple checks of coordination often affected in N-glycosylation defects. Frontiers in Glycosylation
Cardiac auscultation and pulse checks. Murmurs or irregular rhythm may point to structural or conduction problems that need formal testing. hssiem.org
C) Laboratory and pathological tests
Transferrin isoelectric focusing (IEF) or LC-MS of transferrin. The key screening test for N-glycosylation defects; ALG8-CDG shows a type I pattern. PubMed
Serum N-glycan profiling. Confirms a type I assembly/transfer defect and helps separate CDG-I from CDG-II. NCBI
Molecular genetic testing (ALG8 sequencing/exome). Diagnostic confirmation—identifies the pathogenic variants. hssiem.org
Coagulation studies (antithrombin, protein C, factor XI, PT/aPTT). Look for combined factor reductions typical of CDG-I disorders. NCBI
Serum albumin/total protein and liver enzymes. Low albumin supports PLE; enzymes reflect hepatic involvement. Orpha.net
Stool α-1-antitrypsin clearance. Objective test for protein-losing enteropathy when edema or low albumin is present. (Standard PLE test; mechanism discussed in ALG8-CDG.) hssiem.org
D) Electrodiagnostic tests
EEG. Evaluates seizures or suspected subclinical epileptiform activity. hssiem.org
ECG (± Holter). Screens for prolonged QT or conduction blocks reported in ALG8-CDG. hssiem.org
Electroretinography (ERG). Useful if retinal involvement or early visual concerns arise. hssiem.org
E) Imaging tests
Abdominal and renal ultrasound. Checks liver size/texture, ascites, and renal protein-loss or cystic changes reported in some patients. hssiem.org
Echocardiogram. Looks for structural lesions (e.g., septal defects, valve issues) and ventricular size/function changes. hssiem.org
Brain MRI. Explores causes of seizures, tone abnormalities, or developmental delay; helps rule in/out structural contributors described across CDGs. (General CDG practice.) NCBI
Non-pharmacological treatments (therapies and others)
Multidisciplinary care—genetics, GI/hepatology, neurology, nutrition, physio/OT/SLP, ophthalmology. This coordinates complex needs. Mount Sinai Health System+1
Nutrition support with energy-dense feeds—small, frequent feeds; consider nasogastric or gastrostomy feeding if poor intake. Helps growth and reduces fatigue. AAP Publications
Low-long-chain-fat diet with added MCT oil in PLE—MCTs bypass lymph and can reduce protein loss. ScienceDirect
Salt and fluid management for edema/ascites under specialist guidance. Supports circulation. UVA School of Medicine
Albumin replacement protocols (procedural planning; drug in “Medications” below) followed by rest and careful diuretic use—improves swelling symptoms. ScienceDirect
Physiotherapy to improve tone, posture, and gross motor skills; prevents contractures. AAP Publications
Occupational therapy for fine motor skills, daily activities, feeding tools. AAP Publications
Speech-language therapy for feeding/swallow safety and communication. AAP Publications
Developmental and special-education services tailored to learning needs. AAP Publications
Orthotics/serial casting for clubfoot and joint laxity to aid walking. PMC
Vision care—glasses, patching for strabismus, low-vision services. Frontiers in Glycosylation
Skin care routines for dryness and wrinkling; gentle emollients, avoid irritants. PubMed
Vaccinations on schedule to avoid infections that worsen nutrition and edema. (Standard pediatric practice; CDG generally benefit from prevention.) PMC
Infection control at home—hand hygiene, safe food handling. PMC
Regular monitoring plans—growth, albumin, clotting, liver tests, eye and neuro checks. PMC
Genetic counseling for parents and extended family (reproductive options, carrier testing). preventiongenetics.com
Social work and case management for equipment, home nursing, and benefits. Mount Sinai Health System
Care plans for hospital admissions (fluid/albumin/diuretic sequences, coagulation support). ScienceDirect
Palliative/supportive care for severe disease to improve comfort and family support. PMC
Clinical trial awareness through CDG networks (CDG Hub, RD networks) to learn about emerging therapies. CDG Hub
Medication options
Important: Doses below are typical starting ranges for educational purposes. Always individualize with a specialist, especially with liver disease or low albumin.
Levetiracetam (antiepileptic). Class: SV2A modulator. Dose: 10–60 mg/kg/day in 2 doses. When: for seizures. Purpose: reduce seizures. Mechanism: reduces synaptic release. Side effects: sleepiness, irritability; rare mood changes. (General epilepsy standards; CDG commonly have seizures.) PMC
Lamotrigine (antiepileptic). Class: sodium-channel modulator. Dose: slow titration to 1–5 mg/kg/day; watch interactions. Purpose: seizures. Side effects: rash (seek urgent care). PMC
Topiramate (antiepileptic). Dose: ~5–9 mg/kg/day. Purpose: seizures; may help tone. Side effects: appetite loss, stones, acidosis. PMC
Valproate (antiepileptic). Dose: 10–60 mg/kg/day. Note: use with caution in liver disease; discuss risks. Side effects: liver toxicity, thrombocytopenia. PMC
Omeprazole (PPI). Dose: ~0.7–3.5 mg/kg/day. Purpose: reflux, protect esophagus, support feeding. Side effects: GI upset, low magnesium (rare with long use). AAP Publications
Ursodeoxycholic acid. Class: bile acid. Dose: 10–30 mg/kg/day. Purpose: cholestasis/pruritus support. Mechanism: improves bile flow. Side effects: diarrhea. PMC
Fat-soluble vitamins (A, D, E, K) in water-miscible forms. Dose: per weight and levels. Purpose: prevent deficiency with fat malabsorption. Side effects: hypervitaminosis if overdosed. ScienceDirect
Vitamin K. Dose: individualized (e.g., 1–5 mg PO/IV). Purpose: support clotting when INR high. Side effects: injection pain; rare reactions. BioMed Central
Albumin infusions (25% IV). Dose: e.g., 0.5–1 g/kg, then diuretic. Purpose: raise oncotic pressure in PLE/ascites. Side effects: fluid overload if not paired with diuretics. ScienceDirect
Furosemide. Class: loop diuretic. Dose: ~1 mg/kg/dose. Purpose: mobilize fluid after albumin. Side effects: low potassium, dehydration. ScienceDirect
Spironolactone. Class: potassium-sparing diuretic. Dose: ~1–3 mg/kg/day. Purpose: ascites/edema control. Side effects: high potassium, breast tenderness. ScienceDirect
Octreotide (off-label in PLE). Dose: start low (e.g., 1–5 µg/kg/day SC/IV; or LAR monthly). Purpose: reduce intestinal protein loss in selected PLE cases. Side effects: gallstones, glucose changes, GI upset. ScienceDirect+1
Budesonide (targeted steroid) in selected PLE cases. Dose: e.g., 9 mg/day (older children/adults—specialist use). Purpose: decrease gut inflammation and protein loss. Side effects: Cushingoid features, infection risk. Medscape
Cholestyramine for cholestatic itch (pruritus). Dose: per age/weight. Side effects: constipation, binds other meds. PMC
Omega-3 ethyl esters (adjunct) for liver fat/inflammation support in some cases. Dose: per product. Side effects: fishy aftertaste, bleeding risk with anticoagulants. ScienceDirect
Coenzyme Q10 (adjunct antioxidant). Dose: 5–10 mg/kg/day divided. Purpose: mitochondrial support—symptomatic only. Side effects: GI upset. ScienceDirect
Zinc supplementation if deficient (helps gut/skin healing). Dose: per level/age. Side effects: nausea, copper deficiency if overused. ScienceDirect
Vitamin D plus calcium for bone health in malnutrition/low mobility. Dose: per levels. Side effects: high calcium if overdosed. ScienceDirect
Prophylactic anticoagulation in very selected high-risk settings—specialist decision only—because CDG can have clotting imbalance. Side effects: bleeding. BioMed Central
Standard antibiotics/antivirals as needed for infections (not routine). Purpose: prevent decompensation. Side effects: drug-specific. PMC
No disease-specific curative drug exists yet for ALG8-CDG. Some other CDG types respond to sugars (mannose, fucose, galactose), but not ALG8-CDG. BioMed Central
Dietary molecular supplements
MCT oil—start small (e.g., 0.5–1 mL/kg/feed, titrate). Function: calories without using lymph transport. Mechanism: medium chains go directly to the portal vein. ScienceDirect
Water-miscible vitamins A, D, E, K—dose per level. Function: replace fat-soluble vitamins. Mechanism: improved absorption when bile flow is poor. ScienceDirect
Essential fatty acids (linoleic/ALA)—use balanced formulas. Function: skin and cell membrane health. Mechanism: replaces deficits from low long-chain fat intake. ScienceDirect
Calcium + Vitamin D—per level/age. Function: bone mineralization. Mechanism: supports bone turnover under malnutrition. ScienceDirect
Zinc—per level. Function: gut, skin, and immune enzyme cofactor. Mechanism: replaces deficiency that worsens diarrhea/dermatitis. ScienceDirect
Selenium—per level. Function: antioxidant enzymes. Mechanism: supports redox balance in illness. ScienceDirect
Carnitine—10–50 mg/kg/day if low. Function: fatty-acid transport. Mechanism: helps energy use; replace deficiency only. ScienceDirect
Coenzyme Q10—5–10 mg/kg/day. Function: mitochondrial electron transport; antioxidant. Mechanism: supports energy; symptomatic adjunct. ScienceDirect
Probiotics (with caution)—strain-specific, avoid in severe immunocompromise. Function: gut barrier support. Mechanism: microbiome effects. UVA School of Medicine
Oral rehydration with added electrolytes—per WHO recipes. Function: maintain hydration during diarrhea. Mechanism: glucose-sodium co-transport. (Best practice.)
Immunity-booster / regenerative / stem-cell” drugs
There are no approved “immunity booster,” regenerative, or stem-cell drugs for ALG8-CDG. Unsafe products are often marketed online; avoid them. What you can discuss with your team:
Standard immunizations and RSV monoclonal (palivizumab) if your child qualifies—evidence-based infection prevention. PMC
IVIG only if true antibody deficiency is proven—case-by-case. (General CDG practice.) PMC
Octreotide for PLE is not an immune drug, but it can reduce protein loss and indirectly improve nutrition/immunity. ScienceDirect
Clinical trials—check CDG networks for future gene or pathway therapies. CDG Hub
Good nutrition with MCT and micronutrients—the safest “immune support.” ScienceDirect
Avoid unproven stem-cell infusions outside regulated trials—they can be dangerous.
Surgeries or procedures
Gastrostomy tube (G-tube) ± fundoplication—for safe long-term feeding when oral intake is not enough. Improves growth and lowers aspiration risk. AAP Publications
Strabismus surgery—to align the eyes and improve vision development. Frontiers in Glycosylation
Cataract extraction—if lens clouding impairs vision. Frontiers in Glycosylation
Clubfoot correction (e.g., Achilles tenotomy as part of Ponseti casting)—to allow better standing and walking. PMC
Hernia repair—for umbilical/inguinal hernias from chronic ascites or connective-tissue laxity.
Note: Liver or small-bowel transplant is not standard for ALG8-CDG, but very rare, individualized scenarios may consider advanced options for end-stage organ disease after expert review. (General CDG context.) PMC
Prevention tips
Keep vaccinations up to date. PMC
Hand hygiene and safe food prep to cut infection risk. PMC
Early treatment of diarrhea and vomiting to prevent protein loss and dehydration.
Nutrition plans ready for sick days (ORS, extra calories).
Avoid prolonged fasting; use frequent meals or overnight feeds.
Routine monitoring (albumin, liver/coagulation, growth). PMC
All medication reviews with a pharmacist—avoid liver-toxic or interacting drugs.
Protect skin with emollients to prevent breakdown/infection. PubMed
Orthopedic/vision follow-up to prevent long-term disability. PMC+1
Genetic counseling for future pregnancies. preventiongenetics.com
When to see a doctor urgently
New or worsening swelling, shortness of breath, or big abdominal distension.
Fever, persistent vomiting/diarrhea, or poor drinking.
Seizures, reduced alertness, or sudden weakness.
Bleeding or extensive bruising.
Yellow eyes/skin (worsening jaundice), very pale stools, or very dark urine.
These may signal dehydration, severe protein loss, clotting problems, liver trouble, or an infection that needs hospital care. Ovid
What to eat and what to avoid
Eat: small, frequent meals with energy-dense foods.
Use MCT oil as directed to boost calories in PLE. ScienceDirect
Ensure protein in every meal (per dietitian plan).
Water-miscible ADEK vitamins and vitamin D/calcium as prescribed. ScienceDirect
Offer soft textures if chewing/tone is weak; use feeding therapy ideas. AAP Publications
Hydration with oral rehydration solution during illness.
Limit long-chain fats if PLE/cholestasis is present; favor MCT as advised. ScienceDirect
Avoid raw shellfish and unpasteurized foods (liver safety and infection prevention).
Avoid herbal/supplement products with liver toxicity claims unless approved.
Avoid prolonged fasting; use bedtime snacks or continuous feeds when prescribed.
FAQs
1) Is ALG8-CDG inherited?
Yes. It is usually autosomal recessive. A child is affected when both parents pass down one faulty copy. CDG Hub
2) How common is it?
It is very rare; only a few dozen individuals have been reported in the medical literature. PMC
3) What are the first signs?
Feeding problems, diarrhea, swelling from low albumin, poor growth, low muscle tone, and sometimes seizures in infancy. rarediseasesnetwork.org
4) How is it diagnosed?
Doctors often start with transferrin glycoform testing in blood. A genetic test confirms the diagnosis. Mayo Clinic Laboratories+1
5) Is there a cure?
No specific cure yet. Care treats symptoms and prevents complications. Some other CDG types respond to sugar therapy, but not ALG8-CDG. CDG Hub+1
6) Why does my child swell?
Protein can leak into the gut (PLE), lowering blood albumin. Low albumin pulls water into tissues and the belly. Ovid
7) Can PLE be treated?
Yes. Nutrition (MCT diet), albumin infusions plus careful diuretics, and sometimes octreotide can help selected patients. ScienceDirect
8) What about the liver and bleeding?
The liver makes clotting proteins. If they are under-glycosylated or the liver is stressed, bleeding or clots can happen. Vitamin K and specialist care help. BioMed Central
9) Will my child walk or speak?
Many children improve with physio/OT/SLP and appropriate supports. The range is broad and depends on severity. AAP Publications
10) Are the eyes affected?
Some children develop cataracts, retinal degeneration, or strabismus. Regular eye checks are important. Frontiers in Glycosylation
11) Do carriers have symptoms?
People with one ALG8 variant can develop polycystic liver and/or kidney cysts in adulthood; this is different from ALG8-CDG. PMC+1
12) What specialists should we see?
A coordinated team: genetics, GI/hepatology, neurology, ophthalmology, nutrition/therapy services. Mount Sinai Health System
13) Can specific sugars (like mannose or fucose) help?
They help in some other CDGs, but not known to help ALG8-CDG. BioMed Central
14) Are there clinical trials?
CDG groups and networks post updates—ask your team and check trusted registries (CDG Hub, RD Networks). CDG Hub+1
15) What is the outlook?
It varies. Severe cases can have early complications; milder cases can live longer with supportive care. Close follow-up improves outcomes. Frontiers in Glycosylation
Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.
The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members
Last Updated: September 12, 2025.
